MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1

$252,036P50FY2013CANIH

Roswell Park Cancer Institute Corp, Buffalo NY

Investigators

Linked publications & trials

Paper 39372930 Paper 39272943 Paper 39114540 Paper 39087954 Paper 38949179 Paper 38802116 Paper 38667314 Paper 38496424 Paper 37647218 Paper 37436712 Paper 37369443 Paper 37220873 Paper 37009132 Paper 36875325 Paper 36401943 Paper 36210504 Paper 36206753 Paper 36182623 Paper 35537410 Paper 35460379 Paper 35294258 Paper 35254331 Paper 35046055 Paper 35003898 Paper 34789471 Paper 34607898 Paper 34518593 Paper 34162658 Paper 34025677 Paper 33658501 Paper 33619020 Paper 33177175 Paper 33172895 Paper 32905653 Paper 32766851 Paper 32676168 Paper 32663904 Paper 32641237 Paper 32591511 Paper 32546565 Paper 32238380 Paper 32122543 Paper 32028322 Paper 31469419 Paper 31384667 Paper 31265121 Paper 31239549 Paper 31221207 Paper 31211375 Paper 31159617 Paper 31043418 Paper 31001917 Paper 30905014 Paper 30898391 Paper 30730851 Paper 30683880 Paper 30626427 Paper 30559148 Paper 30518816 Paper 30499236 Paper 30487138 Paper 30446565 Paper 30418985 Paper 30390758 Paper 30120411 Paper 30093685 Paper 30062862 Paper 30054336 Paper 29853604 Paper 29742431 Paper 29622465 Paper 29588318 Paper 29555990 Paper 29502561 Paper 29327114 Paper 29301753 Paper 29211900 Paper 29186515 Paper 29141849 Paper 29071675 Paper 29049607 Paper 29029385 Paper 28930807 Paper 28881617 Paper 28864456 Paper 28819352 Paper 28817835 Paper 28633381 Paper 28624153 Paper 28606585 Paper 28495239 Paper 28483269 Paper 28433629 Paper 28392127 Paper 28367538 Paper 28350790 Paper 28300768 Paper 28293802 Paper 28290453 Paper 28239471

Abstract

Genomic instability of ovarian cancer (OvCa) cells and the resulting frequent loss or reduction of HLA expression and function facilitate immune avoidance of this aggressive cancer. The goal of this Project is to develop an effective mode of immunotherapy capable of targeting both MHC-positive and MHC-negative variants of OvCa and counteracting local immune suppression, known to contribute to poor prognosis in OvCa patients. We observed that type-1-polarized DCs (¿DC1s), a novel type of DCs developed by our group, effectively cross-present OvCa-related antigens and induce high numbers of MHC class l-restricted CTLs capable of recognizing defined OvCa-related antigenic epitopes. However aDC1-induced CTLs also express elevated levels of NK receptors, NKG2D- and DNAM1. Such

View original record on NIH RePORTER →